• 1
    Gottschalk S, Rooney CM, Heslop HE. Post-transplant lymphoproliferative disorders. Annu Rev Med 2005; 56: 2944.
  • 2
    Epstein MA, Henle G, Achong BG, Barr YM. Morphological and biological studies on a virus in cultured lymphoblasts from Burkitt's lymphoma. J Exp Med 1965; 121: 761770.
  • 3
    Cohen JI. Epstein-Barr virus infection. N Engl J Med 2000; 343: 481492.
  • 4
    Thorley-Lawson DA. Epstein-Barr virus: Exploiting the immune system. Nat Rev Immunol 2001; 1: 7582.
  • 5
    Kieff E, Rickinson AB. Epstein-Barr virus and its replication. In: KnipeDM, HowleyPM, eds. Fields Virolgy. Philadelphia , PA : Lippincott Williams and Wilkins, 2001: 25752627.
  • 6
    Gordadze AV, Peng R, Tan J et al. Notch1IC partially replaces EBNA2 function in B cells immortalized by Epstein-Barr virus. J Virol 2001; 75: 58995912.
  • 7
    Hofelmayr H, Strobl LJ, Marschall G, Bornkamm GW, Zimber-Strobl U. Activated Notch1 can transiently substitute for EBNA2 in the maintenance of proliferation of LMP1-expressing immortalized B cells. J Virol 2001; 75: 20332040.
  • 8
    Dykstra ML, Longnecker R, Pierce SK. Epstein-Barr virus coopts lipid rafts to block the signaling and antigen transport functions of the BCR. Immunity 2001; 14: 5767.
  • 9
    Kilger E, Kieser A, Baumann M, Hammerschmidt W. Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. Embo J 1998; 17: 17001709.
  • 10
    Babcock GJ, Thorley-Lawson DA. Tonsillar memory B cells, latently infected with Epstein-Barr virus, express the restricted pattern of latent genes previously found only in Epstein-Barr virus-associated tumors. Proc Natl Acad Sci USA 2000; 97: 1225012255.
  • 11
    Sayos J, Wu C, Morra M et al. The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature 1998; 395: 462469.
  • 12
    Callan MF, Tan L, Annels N et al. Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus In vivo. J Exp Med 1998; 187: 13951402.
  • 13
    Kuppers R. B cells under influence: Transformation of B cells by Epstein-Barr virus. Nat Rev Immunol 2003; 3: 801812.
  • 14
    Weiss LM, Movahed LA, Warnke RA, Sklar J. Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. N Engl J Med 1989; 320: 502506.
  • 15
    Mancao C, Altmann M, Jungnickel B, Hammerschmidt W. Rescue of “crippled” germinal center B cells from apoptosis by Epstein-Barr virus. Blood 2005; 106: 43394344.
  • 16
    Raab-Traub N. Epstein-Barr virus in the pathogenesis of NPC. Semin Cancer Biol 2002; 12: 431441.
  • 17
    Klein G. Post-transplantation lymphoproliferative disease. Introduction. Springer Semin Immunopathol 1998; 20: 319323.
  • 18
    Razonable RR, Paya CV. Herpesvirus infections in transplant recipients: Current challenges in the clinical management of cytomegalovirus and Epstein-Barr virus infections. Herpes 2003; 10: 6065.
  • 19
    Martinez OM, Villanueva JC, Lawrence-Miyasaki L, Quinn MB, Cox K, Krams SM. Viral and immunologic aspects of Epstein-Barr virus infection in pediatric liver transplant recipients. Transplantation 1995; 59: 519524.
  • 20
    Taga H, Taga K, Wang F, Chretien J, Tosato G. Human and viral interleukin-10 in acute Epstein-Barr virus-induced infectious mononucleosis. J Infect Dis 1995; 171: 13471350.
  • 21
    Moore KW, De Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19: 683765.
  • 22
    Ding Y, Qin L, Kotenko SV, Pestka S, Bromberg JS. A single amino acid determines the immunostimulatory activity of interleukin 10. J Exp Med 2000; 191: 213224.
  • 23
    Cohen JI, Lekstrom K. Epstein-Barr virus BARF1 protein is dispensable for B-cell transformation and inhibits alpha interferon secretion from mononuclear cells. J Virol 1999; 73: 76277632.
  • 24
    Kawanishi M, Tada-Oikawa S, Kawanishi S. Epstein-Barr virus BHRF1 functions downstream of bid cleavage and upstream of mitochondrial dysfunction to inhibit TRAIL-induced apoptosis in BJAB cells. Biochem Biophys Res Commun 2002; 297: 682687.
  • 25
    Gregory CD, Dive C, Henderson S et al. Activation of Epstein-Barr virus latent genes protects human B cells from death by apoptosis. Nature 1991; 349: 612614.
  • 26
    Kaye KM, Izumi KM, Kieff E. Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc Natl Acad Sci USA 1993; 90: 91509154.
  • 27
    Young LS, Dawson CW, Eliopoulos AG. Epstein-Barr virus and apoptosis: Viral mimicry of cellular pathways. Biochem Soc Trans 1999; 27: 807812.
  • 28
    Cahir-McFarland ED, Davidson DM, Schauer SL, Duong J, Kieff E. NF-kappa B inhibition causes spontaneous apoptosis in Epstein-Barr virus-transformed lymphoblastoid cells. Proc Natl Acad Sci U S A 2000; 97: 60556060.
  • 29
    Kenney JL, Guinness ME, Curiel T, Lacy J. Antisense to the Epstein-Barr virus (EBV)-encoded latent membrane protein 1 (LMP-1) suppresses LMP-1 and bcl-2 expression and promotes apoptosis in EBV-immortalized B cells. Blood 1998; 92: 17211727.
  • 30
    Lee JM, Lee KH, Weidner M, Osborne BA, Hayward SD. Epstein-Barr virus EBNA2 blocks Nur77-mediated apoptosis. Proc Natl Acad Sci USA 2002; 99: 1187811883.
  • 31
    Portis T, Longnecker R. Epstein-Barr virus (EBV) LMP2A mediates B-lymphocyte survival through constitutive activation of the Ras(PI3K(Akt pathway. Oncogene 2004; 23: 86198628.
  • 32
    Dawson CW, George JH, Blake SM, Longnecker R, Young LS. The Epstein-Barr virus encoded latent membrane protein 2A augments signaling from latent membrane protein 1. Virology 2001; 289: 192207.
  • 33
    Dawson CW, Tramountanis G, Eliopoulos AG, Young LS. Epstein-Barr virus latent membrane protein 1 (LMP1) activates the phosphatidylinositol 3-kinase(Akt pathway to promote cell survival and induce actin filament remodeling. J Biol Chem 2003; 278: 36943704.
  • 34
    Saridakis V, Sheng Y, Sarkari F et al. Structure of the p53 binding domain of HAUSP(USP7 bound to Epstein-Barr nuclear antigen 1 implications for EBV-mediated immortalization. Mol Cell 2005; 18: 2536.
  • 35
    Kennedy G, Komano J, Sugden B. Epstein-Barr virus provides a survival factor to Burkitt's lymphomas. Proc Natl Acad Sci USA 2003; 100: 1426914274.
  • 36
    Snow AL, Lambert SL, Natkunam Y, Esquivel CO, Krams SM, Martinez OM. EBV can protect latently infected B cell lymphomas from death receptor-induced apoptosis. J Immunol 2006; 177: 32833293.
  • 37
    Durandy A, Le Deist F, Emile JF, Debatin K, Fischer A. Sensitivity of Epstein-Barr virus-induced B cell tumor to apoptosis mediated by anti-CD95(Apo-1(fas antibody. Eur J Immunol 1997; 27: 538543.
  • 38
    Tepper CG, Seldin MF. Modulation of caspase-8 and FLICE-inhibitory protein expression as a potential mechanism of Epstein-Barr virus tumorigenesis in Burkitt's lymphoma. Blood 1999; 94: 17271737.
  • 39
    Snow AL, Chen LJ, Nepomuceno RR, Krams SM, Esquivel CO, Martinez OM. Resistance to Fas-mediated apoptosis in EBV-infected B cell lymphomas is due to defects in the proximal Fas signaling pathway. J Immunol 2001; 167: 54045411.
  • 40
    Snow AL, Vaysberg M, Krams SM, Martinez OM. EBV B lymphoma cell lines from patients with post-transplant lymphoproliferative disease are resistant to TRAIL-induced apoptosis. Am J Transplant 2006; 6: 976985.
  • 41
    Falco DA, Nepomuceno RR, Krams SM et al. Identification of Epstein-Barr virus-specific CD8+ T lymphocytes in the circulation of pediatric transplant recipients. Transplantation 2002; 74: 501510.
  • 42
    Lewinsohn DM, Bement TT, Xu J et al. Human purified protein derivative-specific CD4+ T cells use both CD95-dependent and CD95-independent cytolytic mechanisms. J Immunol 1998; 160: 23742379.
  • 43
    Katano H, Ali MA, Patera AC, et al. Chronic active Epstein-Barr virus infection associated with mutations in perforin that impair its maturation. Blood 2004; 103: 12441252.
  • 44
    Majewski M, Korecka M, Joergensen J et al. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses. Transplantation 2003; 75: 17101717.
  • 45
    Nepomuceno RR, Balatoni CE, Natkunam Y, Snow AL, Krams SM, Martinez OM. Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas. Cancer Res 2003; 63: 44724480.
  • 46
    Tanner JE, Alfieri C. The Epstein-Barr virus and post-transplant lymphoproliferative disease: Interplay of immunosuppression, EBV, and the immune system in disease pathogenesis. Transpl Infect Dis 2001; 3: 6069.
  • 47
    Gottschalk S, Heslop HE, Rooney CM. Adoptive immunotherapy for EBV-associated malignancies. Leuk Lymphoma 2005; 46: 110.
  • 48
    Hong GK, Gulley ML, Feng WH, Delecluse HJ, Holley-Guthrie E, Kenney SC. Epstein-Barr virus lytic infection contributes to lymphoproliferative disease in a SCID mouse model. J Virol 2005; 79: 1399314003.
  • 49
    Keller SA, Hernandez-Hopkins D, Vider J et al. NF-kappaB is essential for the progression of KSHV- and EBV-infected lymphomas in vivo. Blood 2006; 107: 32953302 Epub 2005 Dec 3227.